ScreenerHero

ALTAltimmune, Inc.

NAS · US · Healthcare · Biotechnology · altimmune.com
3.110USD-0.32%Mkt Cap: 604.95M $P/E: —

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap604.95M $
Enterprise Value283.57M $
Revenue (TTM)31.00K $
Gross Profit-66.69M $
Net Income (TTM)-88.09M $
Revenue/Share0.0000 USD
Last Price3.110 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS02155H2004
Valuation
P/E (Trailing)—
P/E (Forward)-4.41
PEG32.62
EV/EBITDA-2.88
EV/Revenue9147.30
P/S18510.56
P/B1.21
EPS (TTM)-0.72
EPS (Forward)-0.67
52W Range
2.56014% of range6.440
52W High6.440 USD
52W Low2.560 USD
Profitability
Gross Margin0.00%
Oper. Margin-318493.55%
EBITDA Margin0.00%
Profit Margin-214860.98%
ROE-39.17%
ROA-31.47%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-67.53M $
CapEx (TTM)11.00K $
FCF Margin-157374.59%
FCF Yield-8.06%
Net Debt-290.26M $
Net Debt/EBITDA2.94
Balance Sheet
Debt/Equity0.16
Current Ratio26.78
Quick Ratio26.37
Book Value/Sh2.438 USD
Cash/Share1.677 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJan 20, 2017
Pay DateSep 14, 2018
Splits
Last Split1:30
Split DateSep 14, 2018
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.22 USD
Upside (mean)+453.8%
Target Range11.00 USD – 28.00 USD
$11.00+453.8% to mean$28.00
# Analysts9
Ownership
Shares Out.194.52M
Float164.39M
Insiders0.42%
Institutions77.67%
Short Interest
Short Ratio12.1d
Short % Float26.74%
Short % Out.26.71%
Shares Short51.94M
Short (prev mo.)47.63M
Technical
SMA 502.919 (+6.5%)
SMA 2003.695 (-15.8%)
Beta0.17
S&P 52W Chg18.16%
Avg Vol (30d)4.51M
Avg Vol (10d)4.87M
Technical Indicators
RSI (14)58.0
MACD0.0325
MACD Signal0.0219
MACD Hist.+0.0106
BB Upper3.163 USD
BB Middle2.976 USD
BB Lower2.789 USD
BB Width12.54%
ATR (14)0.1663 USD
Vol Ratio (20d)1.18x